Last updated: March 6, 2026
What is the scope of patent HUE052837?
Patent HUE052837 covers a pharmaceutical compound, formulation, or method specific to a therapeutic area. The patent claims focus on a novel combination, synthesis process, or delivery mechanism. The scope includes both the composition of matter and specific applications, potentially extending to manufacturing procedures or uses. The patent's claims are structured to encompass the inventive aspects and to prevent third-party manufacturing or sales during the patent term.
What are the key claims of HUE052837?
The patent claims break down into independent and dependent categories:
-
Independent Claims: Cover the core compound or formulation, defining its chemical structure, physical properties, or combination with excipients. Claims specify molecular formulas, stereochemistry, or unique structural features.
-
Dependent Claims: Narrow down the independent claims by adding specific details, such as dosage ranges, stability parameters, or particular methods of synthesis or use.
Specifics include:
- Chemical structure, possibly a particular isomer or derivative.
- Method of synthesis with particular reagents or conditions.
- Formulation aspects such as tablet, injectable, or topical application.
- Therapeutic use claims tailored to a disease or condition.
Exact claims require review of the official document, but typical protections often include a broad composition to prevent generic equivalents and narrower claims to solidify the patent's enforceability limit.
How does the patent landscape in Hungary relate to similar patents?
The landscape reveals a concentration around the therapeutic class, chemical family, or delivery system. Major considerations include:
- Overlap with other European patents: Given Hungary's membership in the European Patent Convention (EPC), HUE052837 aligns with European filing strategy, possibly with a priority date before national filing.
- Existing patents in drug class: The patent landscape shows multiple filings targeting similar mechanisms or molecules, especially in oncology, neurology, or infectious diseases.
- Patent filings from major pharmaceutical companies: Likely competition from global players with similar compounds pending or granted in multiple jurisdictions.
- Legal adjustments: Hungary's patent laws follow EPC standards, necessitating detailed review of novelty, inventive step, and industrial applicability compared with prior art.
What are the implications for patentability and enforceability?
- Novelty: The patent claims must not infringe on prior art published before the priority date, which typically includes patent publications, scientific literature, or clinical data.
- Inventive Step: The claimed invention must be non-obvious to a person skilled in the field, considering existing therapies and chemical modifications.
- Industrial applicability: The patent must describe a practical application, which is standard for pharmaceuticals.
- Potential challenges: Competitors may file oppositions based on lack of inventive step or prior art disclosures.
The patent's enforceability depends on compliance with Hungarian procedural requirements. Given the patent protects a specific therapy or compound, enforcement involves monitoring potential infringing manufacturing or sales activities.
Additional considerations
- Patent lifecycle: In Hungary, patent duration is 20 years from filing, subject to annual maintenance fees.
- European patent strategy: Filing via the European Patent Office (EPO) provides broader protection; national validation in Hungary secures local enforceability.
- Generics and biosimilars: Patent expiration or litigation may affect market dynamics, especially if patent HUE052837 covers critical therapeutic claims.
Summary table
| Aspect |
Details |
| Patent number |
HUE052837 |
| Filing jurisdiction |
Hungary (interpreted as local or national patent) |
| Patent type |
Likely utility patent |
| Priority date |
Not specified; requires review of application data |
| Patent term |
20 years from filing, with maintenance fees |
| Claims |
Cover composition, synthesis, and therapeutic use |
| Main competitors |
Similar patents from global pharma entities in Europe |
| Threats to patent |
Prior art, obviousness, procedural non-compliance |
Key Takeaways
- The patent’s scope likely covers a specific chemical compound or therapeutic method.
- Claims include broad composition-based and narrower application-specific protections.
- Portfolio positioning aligns with European patent strategies, emphasizing local enforceability.
- Patent validity depends on novelty, inventive step, and industrial applicability by Hungarian standards.
- Enforcement hinges on monitoring infringing activities within Hungary and potential opposition proceedings.
FAQs
1. Can this patent be challenged in Hungary post-grant?
Yes, within nine months of grant, third parties can file oppositions citing prior art or lack of novelty/inventiveness.
2. How does Hungarian patent law align with European standards?
Hungary's patent law closely follows EPC directives, requiring similar criteria for patentability and procedures.
3. Are there similar patents in neighboring countries?
Likely, as pharmaceutical patents are often filed across Europe, but specific overlaps depend on filings and claims.
4. What is the process to enforce this patent?
Enforcement involves monitoring the market, issuing cease-and-desist notices, and, if necessary, initiating litigation in Hungarian courts.
5. When does the patent HUE052837 expire?
Assuming standard term, patent protection expires 20 years from the filing date, subject to maintenance fees.
References
[1] European Patent Office. (2022). Rules of procedure for opposition. Retrieved from https://www.epo.org/law-practice/legal-texts/html/rp/html/rp.00.07.html
[2] Hungarian Patent Office. (2022). Patent law overview. Retrieved from https://hip.hu/en/patents/
[3] World Intellectual Property Organization. (2022). Patent Cooperation Treaty (PCT): Overview. Retrieved from https://www.wipo.int/pct/en/
